: Minimal residual disease detected by hematologic analysis, cytogenetic techniques, qRT-PCR based on mRNA and Q-PCR based on gDNA. Eight CML patients were the object of our study. We monitored minimal residual disease by both hematologic analysis, CBA and I-FISH, and molecular techniques in 8 years of follow-up. Conventional qRT-PCR was performed. The BCR-ABL1/ABL1 ratios were multiplied by the conversion factor of the Bergamo laboratory to set the results on international scale (IS). The same samples were tested by Q-PCR based on genomic DNA. Patient specific Q-PCR assays were developed on the basis of genomic breakpoint and the percentage of leukemic cells was calculated by using the following formula: %LC= (2/(2 ∆ct +1))*100, where ∆Ct is the difference between the amplification cycles of the BCR-ABL1 and BCR reactions. The number of LC was then calculated by multiplying the total number of cells analyzed in each sample for the percentage of LC calculated by the ∆Ct formula. Assuming that the content of DNA per cell is 5.7 pg, the total analyzed cell number was calculated by dividing the total of pg of gDNA analyzed in each reaction of real-time by 5.7 pg.

